JiangXi Tianxin Pharmaceutical Co., Ltd. (SHA:603235)
China · Delayed Price · Currency is CNY 25.51
-0.34 (-1.32%)
Oct 27, 2026, 4:00 PM EDT
SHA:603235 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 2,556 | 2,322 | 2,181 | 1,851 | 2,253 | 2,466 |
Other Revenue | 22.74 | 22.74 | 28 | 30.6 | 51.71 | 55.97 |
| 2,579 | 2,345 | 2,209 | 1,882 | 2,305 | 2,522 | |
Revenue Growth | 15.87% | 6.18% | 17.35% | -18.34% | -8.63% | 9.50% |
Cost of Revenue | 1,558 | 1,369 | 1,288 | 1,174 | 1,450 | 1,432 |
Gross Profit | 1,021 | 975.8 | 920.91 | 708.11 | 854.67 | 1,090 |
Selling, General & Admin | 231.8 | 218.12 | 177.02 | 169.21 | 174.88 | 140.19 |
Research & Development | 129.75 | 100.52 | 103.82 | 111.96 | 89.46 | 58.94 |
Other Operating Expenses | 54.49 | 24.44 | 17.86 | 19.81 | 21.97 | 22.77 |
Operating Expenses | 419.23 | 343.35 | 301.92 | 299.32 | 282.46 | 228.3 |
Operating Income | 602.13 | 632.45 | 619 | 408.79 | 572.21 | 862.11 |
Interest Expense | - | -0.47 | -2.48 | -2.1 | -6.93 | -12.67 |
Interest & Investment Income | 25.71 | 46.32 | 64.81 | 76.54 | 22.88 | 4.34 |
Currency Exchange Gain (Loss) | -10.52 | -10.52 | 54.19 | 31.24 | 82.37 | -26.95 |
Other Non Operating Income (Expenses) | -28.92 | -1.26 | -1.25 | 0.32 | -1.74 | -1.61 |
EBT Excluding Unusual Items | 588.41 | 666.52 | 734.26 | 514.79 | 668.79 | 825.22 |
Gain (Loss) on Sale of Investments | -0.47 | - | 2.24 | - | 4.33 | -6.61 |
Gain (Loss) on Sale of Assets | -0.5 | -1.49 | -1.07 | -0.09 | -1.07 | -2.14 |
Asset Writedown | 7.99 | -0.92 | -0.61 | -0.19 | -0.86 | - |
Other Unusual Items | 60 | 40.31 | 36.95 | 50.66 | 54.57 | 56.91 |
Pretax Income | 655.43 | 704.42 | 771.77 | 565.17 | 725.76 | 873.37 |
Income Tax Expense | 103.89 | 112.84 | 120.55 | 89.32 | 103.64 | 129.49 |
Net Income | 551.54 | 591.58 | 651.22 | 475.85 | 622.12 | 743.89 |
Net Income to Common | 551.54 | 591.58 | 651.22 | 475.85 | 622.12 | 743.89 |
Net Income Growth | -10.62% | -9.16% | 36.85% | -23.51% | -16.37% | -16.14% |
Shares Outstanding (Basic) | 437 | 438 | 437 | 437 | 412 | 394 |
Shares Outstanding (Diluted) | 437 | 438 | 437 | 437 | 412 | 394 |
Shares Change | 0.67% | 0.26% | 0.11% | 5.96% | 4.68% | -0.10% |
EPS (Basic) | 1.26 | 1.35 | 1.49 | 1.09 | 1.51 | 1.89 |
EPS (Diluted) | 1.26 | 1.35 | 1.49 | 1.09 | 1.51 | 1.89 |
EPS Growth | -11.21% | -9.40% | 36.70% | -27.82% | -20.11% | -16.00% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 381.44 | 48.68 | -567.3 | 193.61 | 346.11 | 603.13 |
Free Cash Flow Per Share | 0.87 | 0.11 | -1.30 | 0.44 | 0.84 | 1.53 |
Dividend Per Share | 0.550 | 0.550 | 0.680 | 0.500 | 0.710 | - |
Dividend Growth | -19.12% | -19.12% | 36.00% | -29.58% | - | - |
Gross Margin | 39.60% | 41.61% | 41.70% | 37.63% | 37.08% | 43.23% |
Operating Margin | 23.35% | 26.97% | 28.03% | 21.72% | 24.83% | 34.18% |
Profit Margin | 21.38% | 25.23% | 29.49% | 25.29% | 26.99% | 29.49% |
Free Cash Flow Margin | 14.79% | 2.08% | -25.69% | 10.29% | 15.02% | 23.91% |
EBITDA | 814.32 | 818.53 | 770.25 | 544.64 | 695.81 | 969.57 |
EBITDA Margin | 31.57% | 34.91% | 34.88% | 28.94% | 30.19% | 38.44% |
D&A For EBITDA | 212.19 | 186.08 | 151.25 | 135.85 | 123.6 | 107.46 |
EBIT | 602.13 | 632.45 | 619 | 408.79 | 572.21 | 862.11 |
EBIT Margin | 23.35% | 26.97% | 28.03% | 21.72% | 24.83% | 34.18% |
Effective Tax Rate | 15.85% | 16.02% | 15.62% | 15.80% | 14.28% | 14.83% |
Revenue as Reported | 714.1 | 2,345 | 2,209 | 1,882 | 2,305 | 2,522 |